Dexamethasone improves antiemetic control in lung cancer patients treated with chemotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 434s Year: 2007
Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Metformin improves survival in lung cancer patients receiving EGFR-TKIs therapy> Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018
Anti-cancer therapy and monitoring plasma concentration of carboplatin in lung cancer patients receiving hemodialysis Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Gemsitabine plus cisplatine therapy in local advanced NSCLC Source: Eur Respir J 2007; 30: Suppl. 51, 434s Year: 2007
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019 Year: 2020
Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017
Comparing different initial doses of afatinib used as first-line treatment for patients with stage IV lung adenocarcinoma Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017
Predictive role of MMP-2 genetic variants on severe hematologic toxicity of NSCLC patients treated with first-line, platinum-based chemotherapy Source: Annual Congress 2011 - Genetics of airway diseases and treatment Year: 2011
Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily at 1250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006
A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002
Maintenance treatment with erlotinib after induction chemotherapy for advanced NSCLC Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017 Year: 2018
A randomised phase III trial by the European lung cancer working party comparing sequential administration of cisplatin-based chemotherapy followed by a taxan and a cisplatin-based standard chemotherapy, with the use of taxan as salvage treatment Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006
Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Survival and respiratory effects in NSCLC patients after treatment with inhaled carboplatin Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010